Analyst Price Targets — BDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 6, 2026 12:40 pm | — | Evercore ISI | $180.00 | $154.60 | TheFly | Becton Dickinson price target lowered to $180 from $190 at Evercore ISI |
| May 11, 2026 9:26 am | — | Barclays | $204.00 | $149.43 | TheFly | Becton Dickinson price target raised to $204 from $202 at Barclays |
| April 17, 2026 11:40 am | Jason Bednar | Piper Sandler | $159.00 | $154.82 | TheFly | Becton Dickinson price target lowered to $159 from $170 at Piper Sandler |
| April 14, 2026 11:17 am | — | RBC Capital | $175.00 | $155.43 | TheFly | Becton Dickinson price target lowered to $175 from $195 at RBC Capital |
| April 10, 2026 4:09 am | David Roman | Goldman Sachs | $167.00 | $154.42 | TheFly | Becton Dickinson resumed with a Neutral at Goldman Sachs |
| February 10, 2026 1:54 pm | Shagun Singh | RBC Capital | $172.00 | $170.14 | TheFly | Becton Dickinson price target lowered to $172 from $210 at RBC Capital |
| February 10, 2026 12:15 pm | Matt Miksic | Barclays | $202.00 | $207.39 | TheFly | Becton Dickinson reinstated with an Overweight at Barclays |
| February 10, 2026 11:28 am | — | Piper Sandler | $170.00 | $207.39 | TheFly | Becton Dickinson price target lowered to $170 from $205 at Piper Sandler |
| January 28, 2026 11:51 am | Jason Bednar | Piper Sandler | $161.16 | $159.91 | TheFly | Becton Dickinson price target raised to $205 from $190 at Piper Sandler |
| January 7, 2026 12:34 pm | — | Stifel Nicolaus | $169.03 | $161.45 | TheFly | Becton Dickinson price target raised to $215 from $210 at Stifel |
Latest News for BDX
FRANKLIN LAKES, N.J., July 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver could benefit from greater adoption of GLP-1 drugs.
Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.
Becton, Dickinson and Company is undervalued, trading at 12–13x P/E despite forecasted 7%–8% annual growth and improving fundamentals. BDX's sector-wide pressures are driven by cautious hospital spending, higher rates, and capital rotation into AI, but its core operations remain robust. BDX maintains a BBB rating, conservative leverage, a 2.78% dividend with 44+ years of increases, and is executing $2B in buybacks…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.